|
See related Symbicort information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
DKSH |
|
Contents |
Per 80/4.5 dose Budesonide 80 mcg, formoterol fumarate dihydrate 4.5 mcg. Per 160/4.5 dose Budesonide 160 mcg, formoterol fumarate dihydrate 4.5 mcg. Per delivered dose (Forte) Budesonide 320 mcg, formoterol fumarate 9 mcg |
|
Indications |
Treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β-agonist) is appropriate. Patients not adequately controlled w/ inhaled corticosteroids & "as needed" inhaled short-acting β2-agonists. Patients already adequately controlled on both inhaled corticosteroids & long-acting β2-agonists. Symptomatic treatment of severe COPD & a history of repeated exacerbations despite therapy w/ long-acting bronchodilators.
Click to view Symbicort detailed prescribing infomation |
|
Dosage |
Asthma Symbicort Single inhaler therapy Adult & adolescent ≥12 yr 2 inhalations (of either strength) once-bid or 1 inhalation bid. Patients should take additional inhalations as needed in response to symptoms. Up to 12 inhalations/day may be used temporarily. Childn ≥6 yr 1 inhalation of 80/4.5 mcg dose once-bid. Up to 8 inhalations/day may be used temporarily. Regular maintenance therapy Adult ≥18 yr 1-2 inhalations (of either strength) bid, max 4 inhalations bid. Adolescent 12-17 yr 1-2 inhalations (of either strength) bid. Childn ≥6 yr 1-2 inhalations of 80/4.5 mcg dose bid. Symbicort Forte Adult ≥18 yr 1-2 inhalations bid. Adolescents 12-17 yr 1 inhalation bid. Reassess asthma therapy regularly & titrate to the lowest dose at which effective control of symptoms is maintained. COPD Adult 2 inhalations bid of 160/4.5 mcg dose, or 1 inhalation bid of Symbicort Forte.
Click to view Symbicort detailed prescribing infomation |
|
Overdosage |
View Symbicort overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Initial management of asthma. Childn <6 yr.
Click to view Symbicort detailed prescribing infomation |
|
Special Precautions |
Thyrotoxicosis, pheochromocytoma, DM, untreated hypokalemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe HTN, aneurysm or other severe CV disorder. Patients w/ prolongation of the QTc-interval. Acute severe asthma. Pregnancy & lactation.
Click to view Symbicort detailed prescribing infomation |
|
Adverse Drug Reactions |
Tremor, palpitation, headache, oral candidiasis, mild throat irritation, coughing, hoarseness.
View ADR Monitoring Form |
|
Drug Interactions |
Ketoconazole, β-adrenergic blockers, quinidine, disopyramide, procainamide, phenothiazines, terfenadine, MAOIs, TCA, levodopa, thyroxine, oxytocin, alcohol, halogenated anesth, digitalis glycosides.
View more drug interactions with Symbicort |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Symbicort detailed prescribing infomation |
|
Storage |
View Symbicort storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Symbicort description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Symbicort mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
